More compliance issues for MTP, this time for Benesis subsidiary
This article was originally published in Scrip
Mitsubishi Tanabe Pharma's (MTP) wholly owned blood products subsidiary Benesis has received a notification from Japan's ministry of health, labour and welfare that one of its plants did not fully comply with certain aspects of good manufacturing practice (GMP) regulations.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.